×

Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Gunter Ditzinger named as successor

BASEL, Switzerland, Aug. 28, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Basilea named Dr. Günter Ditzinger, currently Head of Pharmaceutics, to succeed Dr. Heinze-Krauss in the role of Chief Technology Officer and as a member of the management committee effective February 1, 2016.

Dr. Ditzinger joined Basilea in 2002 as CMC Project Leader & Pharmaceutical Development Manager. He was promoted in 2009 to Head of Pharmaceutics in which position he led the pharmaceutical development and manufacturing group and acted as Dr. Heinze-Krauss' deputy. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.

Dr. Ditzinger holds a PhD in Pharmaceutical Technology from the Johann Wolfgang Goethe University in Frankfurt/Main, Germany.

Ronald Scott, Basilea's Chief Executive Officer, commented: "We are very pleased that Dr. Günter Ditzinger will assume the role of Chief Technology Officer of the company following Dr. Ingrid Heinze-Krauss' retirement. Günter has profound knowledge and broad experience in all aspects of technical development and operations, from early stage development through the commercial phase. Günter is also uniquely qualified as a deputy head and longstanding member of the Technical Operations management team to succeed Dr. Heinze-Krauss as Chief Technology Officer. Dr. Ingrid Heinze-Krauss joined Basilea at its founding in 2000. She established Basilea's Technical Operations department and has managed the group since 2004. We wish to sincerely thank Ingrid for her commitment and valuable contributions to Basilea's success during all these years."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Peer Nils Schröder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com
Barbara Zink, PhD, MBA
Head Corporate Development

+41 61 606 1233
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Press release (PDF) http://hugin.info/134390/R/1948093/707570.pdf

HUG#1948093

Source:Basilea Pharmaceutica Ltd.